IP Library Granted Patent US 7,910,562
Granted Patent B2
US 7,910,562 · App. 10/081,922 · Granted Mar 22, 2011

Method of delivering genes into antigen presenting cells of the skin

Assignee: Genetic Immunity, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,910,562
App. No.
10/081,922
Granted
Mar 22, 2011
Kind
B2
Abstract

A molecular delivery complex specific to antigen-presenting cells is formed from a non-viral gene delivery system complexed with foreign genetic material. The complex then enters the targeted cells through a specific receptor and overcomes the degradation mechanism, so that functional uptake of the foreign genetic material, or transduction, of the cell, results in gene expression. The invention also includes a method for genetic immunization without a needle.

Claims (7)

1. A method of transfecting antigen presenting cells, the steps comprising selecting a gene delivery complex that transfects antigen presenting cells, comprising DNA and glucose or a polyethylenimine derivative, and administering the complex by applying the complex without the use of a needle to the skin or mucosa surfaces of an animal, wherein said DNA comprises a nucleic acid sequence encoding at least one immunogenic protein operatively linked to a promoter, and whereby antigen presenting cells of said skin or mucosa are transfected.

2. The method of claim 1 , wherein the polyethyleneimine derivative targets the mannose receptor found on the surface of antigen presenting cells.

3. The method of claim 1 , wherein the derivative is mannosylated polyetheylenimine.

4. The method of claim 3 , wherein the complex comprises a 5:1 ratio of mannosylated polyethylenimine nitrogen per DNA phosphate.

5. The method of claim 1 , wherein the gene delivery complex is added to a glucose solution.

6. The method of claim 5 , wherein the glucose solution is 5-10% glucose.

7. The method of claim 1 , wherein the derivative is a sugar-modified polyethylenimine.

Assignments (2)
SECURITY AGREEMENT Recorded Sep 28, 2007
From: GENETIC IMMUNITY, LLP
To: TRIDENT GROWTH FUND, LLP; WILSON, WILL; PRONTO, ROD; WALTON, STEVE; VELA, DANNY; SASSER, FORD; BROWDER, ANDY; WILSON, HILTON
Reel/Frame 019892/0606 →
SECURITY AGREEMENT Recorded Aug 31, 2007
From: GENETIC IMMUNITY, LLC
To: WILSON, HILTON; BROWDER, ANDY; TRIDENT GROWTH FUND, LP; VELA, DANNY; SASSER, FORD; RODMAN & RENSHAW, LLC; PRONTO INVESTMENTS, LTD; WILSON, WILL; WALTON, STEVE
Reel/Frame 019767/0755 →
Continuity (3)
Division 09153198 · Sep 15, 1998
Provisional Application 60058933 · Sep 15, 1997
Related Publication 20020193333A1 · Dec 19, 2002